96 related articles for article (PubMed ID: 1879971)
21. Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta.
Belardelli F; Proietti E; Ciolli V; Sestili P; Carpinelli G; Di Vito M; Ferretti A; Woodrow D; Boraschi D; Podo F
Int J Cancer; 1989 Jul; 44(1):116-23. PubMed ID: 2787294
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.
Sala A; Gresser I; Chassoux D; Maury C; Santodonato L; Eid P; Maunoury MT; Barca S; Cianfriglia M; Belardelli F
Cancer Res; 1992 May; 52(10):2880-9. PubMed ID: 1581903
[TBL] [Abstract][Full Text] [Related]
23. Importance of interferon alpha in the resistance of allogeneic C57B1/6 mice to the multiplication of Friend erythroleukemia cells in the liver.
Gresser I; Maury C; Bandu MT; Belardelli F
Int J Cancer; 1990 Feb; 45(2):364-71. PubMed ID: 2406205
[TBL] [Abstract][Full Text] [Related]
24. Intranasal administration of IFN-alpha/beta inhibits the development of visceral tumor metastases.
Kaido TJ
J Interferon Cytokine Res; 1997 Jan; 17(1):31-6. PubMed ID: 9041469
[TBL] [Abstract][Full Text] [Related]
25. Studies on the expression of H-2 antigens in non-metastatic and highly metastatic Friend erythroleukemia cells: correlation with the in vivo behaviour of tumor cells.
Ferrantini M; Pulciani S; Proietti E; Lespinats G; Anastasi A; Ciolli V; Rizza P; Belardelli F
Clin Exp Metastasis; 1989; 7(6):609-25. PubMed ID: 2476272
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
Santodonato L; Ferrantini M; Palombo F; Aurisicchio L; Delmastro P; La Monica N; Di Marco S; Ciliberto G; Du MX; Taylor MW; Belardelli F
Cancer Gene Ther; 2001 Jan; 8(1):63-72. PubMed ID: 11219495
[TBL] [Abstract][Full Text] [Related]
27. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
Kaido T; Maury C; Schirrmacher V; Gresser I
Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
[TBL] [Abstract][Full Text] [Related]
28. Effect of mouse interferon alpha/beta on the expression of H-2 (class I) antigens and on the levels of 2'-5' oligoadenylate synthetase activity in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice.
Locardi C; Belardelli F; Federico M; Romeo G; Affabris E; Gresser I
J Biol Regul Homeost Agents; 1987; 1(4):189-94. PubMed ID: 3332546
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.
Onozaki K; Urawa H; Tamatani T; Iwamura Y; Hashimoto T; Baba T; Suzuki H; Yamada M; Yamamoto S; Oppenheim JJ
J Immunol; 1988 Jan; 140(1):112-9. PubMed ID: 3275716
[TBL] [Abstract][Full Text] [Related]
30. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression.
Proietti E; Tritarelli E; Gabriele L; Testa U; Greco G; Pelosi E; Gabbianelli M; Belardelli F; Peschle C
Cancer Res; 1993 Feb; 53(3):569-76. PubMed ID: 8425189
[TBL] [Abstract][Full Text] [Related]
31. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
32. Generation of mouse natural killer (NK) cell activity: effect of interleukin-2 (IL-2) and interferon (IFN) on the in vivo development of natural killer cells from bone marrow (BM) progenitor cells.
Riccardi C; Giampietri A; Migliorati G; Cannarile L; D'Adamio L; Herberman RB
Int J Cancer; 1986 Oct; 38(4):553-62. PubMed ID: 2944847
[TBL] [Abstract][Full Text] [Related]
33. Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize.
Belardelli F; Ferrantini M; Maury C; Santurbano L; Gresser I
Int J Cancer; 1984 Sep; 34(3):389-95. PubMed ID: 6207117
[TBL] [Abstract][Full Text] [Related]
34. Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host.
Greco G; Gabriele L; Rozera C; Venditti M; Belardelli F; Proietti E
Int J Cancer; 1995 Jul; 62(2):184-90. PubMed ID: 7622294
[TBL] [Abstract][Full Text] [Related]
35. Oromucosal interferon therapy: marked antiviral and antitumor activity.
Tovey MG; Maury C
J Interferon Cytokine Res; 1999 Feb; 19(2):145-55. PubMed ID: 10090400
[TBL] [Abstract][Full Text] [Related]
36. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.
Santodonato L; D'Agostino G; Santini SM; Carlei D; Musiani P; Modesti A; Signorelli P; Belardelli F; Ferrantini M
Gene Ther; 1997 Nov; 4(11):1246-55. PubMed ID: 9425449
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional induction of H2 (class I) antigens and beta 2 microglobulin by interferon-gamma in interferon-sensitive and interferon-resistant Friend leukemia cells.
Coccia E; Marziali G; Fiorucci G; Romeo G; Affabris E; Battistini A; Rossi GB
J Biol Regul Homeost Agents; 1992; 6(1):21-5. PubMed ID: 1442172
[TBL] [Abstract][Full Text] [Related]
38. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.
Dvorak HF; Gresser I
J Natl Cancer Inst; 1989 Apr; 81(7):497-502. PubMed ID: 2921774
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens.
Gresser I; Belardelli F; Maury C; Tovey MG; Maunoury MT
Int J Cancer; 1986 Aug; 38(2):251-7. PubMed ID: 2426208
[TBL] [Abstract][Full Text] [Related]
40. The effect of murine interferon-alpha/beta on an established Rauscher murine leukemia virus-induced erythroleukemia in BALB/c mice.
Hekman RA; Trapman J
Int J Cancer; 1985 Apr; 35(4):515-20. PubMed ID: 2580803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
